Omalizumab is designed to bind human IgE, limiting mast cell degranulation and inflammatory mediator release (41).As the largest trial of omalizumab in atopic dermatitis to date and the first to demonstrate positive clinical results, it found significant improvement in omalizumab in the treatment of severe atopic dermatitis and severe allergies in children, after 24 weeks of treatment, The mean difference in the target SCORAD index was significant between the treatment group and the control group. Here, IGHE is linked to allergic disease.